While considerably less is known about the CNS effects of GIP compared to GLP-1 and glucagon, dual GIP/GLP-1 RA treatment has shown positive effects on animal models of Alzheimer’s disease and Parkinson’s disease (Hölscher, 2018). This evidence concerns the gene GCG and early-onset autosomal dominant Alzheimer disease.